LTR Pharma doses first patient with SPONTAN viagra nasal spray via TGA

Australia’s healthcare regulator TGA has enabled LTR Pharma (ASX:LTP) to dose the first patient with viagra nasal spray product SPONTAN.

Patients were prescribed through one select clinic managing a special access scheme on behalf of the TGA.

“The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma,” company chair Lee Rodne said.

“It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment.”

Rodne also noted the move allows the company to oversee real-world use of the product.

“We see SPONTAN as a valuable addition to our therapeutic capability,” Restorative Sexual Health Clinic founder Melissa Barrett said.

In the background, the company is gearing up to promote the drug and its backing science to international conferences and publications.

LTP last traded at 73cps.